Delcath Systems (NASDAQ:DCTH) Hits New 1-Year High – Should You Buy?

Delcath Systems, Inc. (NASDAQ:DCTH)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $16.44 and last traded at $15.89, with a volume of 13276 shares trading hands. The stock had previously closed at $16.25.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a report on Tuesday, January 14th. Craig Hallum upped their price objective on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Delcath Systems has an average rating of “Moderate Buy” and an average target price of $22.25.

Delcath Systems Price Performance

The business has a fifty day moving average price of $12.87 and a two-hundred day moving average price of $10.59. The firm has a market capitalization of $519.19 million, a price-to-earnings ratio of -11.97 and a beta of 0.86.

Hedge Funds Weigh In On Delcath Systems

Institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. acquired a new stake in Delcath Systems in the third quarter valued at $808,000. Renaissance Technologies LLC acquired a new position in shares of Delcath Systems in the 2nd quarter valued at about $694,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Delcath Systems during the fourth quarter worth $204,000. Jane Street Group LLC bought a new stake in shares of Delcath Systems in the 3rd quarter valued at approximately $110,000. Finally, Barclays PLC bought a new position in Delcath Systems during the third quarter valued at about $104,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.